• 1 January 1981
    • journal article
    • research article
    • Vol. 4  (2) , 173-176
Abstract
A new synthetic anthraquinone, dihydroxyanthraquinone (DHAQ), was tested as a single agent and in combination with whole-body x-irradiation in mice bearing [mouse] L1210 leukemia cells in the ascites form. DHAQ alone had significant antitumor activity as evidenced by prolonged mean survival times; radiation was ineffective. The combination of the 2 modalities produced a therapeutic benefit greater than that produced by either agent alone; mean survival times were increased and a number of eures (animals alive at 30 days) were produced. The potential of using DHAQ and radiation in a combined modality therapeutic approach was suggested.